Delta Cafés and the Champalimaud Foundation have announced a new scientific partnership aimed at strengthening breast cancer research in Portugal, including a pioneering study examining the potential relationship between coffee consumption and breast cancer outcomes.
The agreement will support the expansion of the Breast Cancer Research Program (BCRP) within the Champalimaud Foundation’s Breast Department. According to the organizations, the partnership will fund a new line of scientific research focused on understanding how coffee and its bioactive compounds may influence breast cancer prevention, treatment, and patient wellbeing.
The research initiative is being fully funded by Delta Cafés, which stated that the partnership reflects its commitment to supporting scientific knowledge, innovation, and health-related research. The project represents one of the first dedicated studies of its kind in Portugal examining coffee consumption in relation to breast cancer.
Coffee is the second most consumed beverage globally after water and contains hundreds of bioactive compounds, including caffeine, polyphenols, and antioxidants. Researchers are increasingly studying the effects of these compounds on various aspects of human health and disease management.
According to the organizations, existing scientific evidence suggests there may be positive associations between coffee consumption and factors such as quality of life, fatigue management, body composition, and interactions with breast cancer treatments. However, further scientific and clinical investigation is needed to better understand these relationships and address current knowledge gaps.
The new research programme will be conducted using scientific and methodological approaches intended to strengthen evidence regarding coffee’s potential role in breast cancer care and outcomes.
In addition to the specific coffee-related studies, the funding will also contribute to the broader objectives of the Breast Cancer Research Program. The programme supports research across multiple areas, including early diagnosis, innovative treatment methods, integration of new clinical practices, and advancements in patient care.
Champalimaud Foundation President Leonor Beleza described the partnership as an important contribution to ongoing efforts to combat breast cancer and improve scientific understanding of the disease. She noted that the support provided by Delta Cafés and the Nabeiro family demonstrates a commitment to advancing medical research and supporting future healthcare innovation.
Delta Cafés Chief Executive Officer Rui Miguel Nabeiro emphasized that innovation and investment in scientific knowledge are central to the company’s long-term vision. He stated that the partnership aims not only to study coffee itself, but also to explore how scientific research can contribute to improving health and wellbeing for patients.
The organizations highlighted that the collaboration is intended to support independent, high-quality scientific research in Portugal while contributing to broader international efforts to improve breast cancer prevention, treatment, and quality of life outcomes for patients.
